“ZAMONAVIY BIOLOGIYANING DOLZARB MUAMMOLARI VA
RIVOJLANISH ISTIQBOLLARI”
xalqaro ilmiy-amaliy anjuman materiallari
adu.uz
universaljurnal.uz
11
BRIDGING NANOSCIENCE AND PARASITOLOGY: AMINE-FUNCTIONALIZED
CELLULOSE NANOFIBERS WITH AMPHOTERICIN B AND VITAMIN B12 FOR
PRECISION DRUG DELIVERY IN LEISHMANIASIS TREATMENT
Bhakti Patel
1
, Gautam Priyadarshi
1
, Dipak Kumar Sahoo
2
, and Ashish Patel
1
*
1
Department of Life Sciences, Hemchandracharya North Gujarat University, Patan-384265,
Gujarat, India; bhaktipatel2233@gmail.com (B.P.); priyadarshigautam411@gmail.com (G.P.)
2
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State
University, Ames, Iowa, USA;
*Corresponding author: Ashish Patel (uni.ashish@gmail.com (A.P.))
KEYWORDS: Amphotericin B, cellulose nanofiber, Vitamin B12, Leishmania
donovani, cytotoxicity, MTT assay
ABSTRACT
Leishmaniasis is a globally neglected infectious disease that is caused by protozoan parasites.
The treatment of leishmaniasis is constrained and frequently associated with serious side effects.
Amphotericin B is a highly effective anti-leishmanial drug; however, its oral administration is
restricted by its low bioavailability and toxicity. To address this problem, a novel formulation,
VitB12-PEG4000-AmB-CNFs, was developed for oral delivery of AmB. The formulation showed a
particle size of 490 nm with a surface charge of 28.53, and the BET surface area of the CNFs was
42.08 m2/g facilitated drug loading capacity. FTIR and XRD confirmed the functionalization, loading
of the drug, and encapsulation of the conjugates. The formulation was observed in SEM images with
irregular surface and multi-layered functionalization of VitB12-PEG4000 conjugates on AmB-CNFs,
supporting that EDS spectra showed an increase in the% weight of N. VitB12-PEG4000-AmB-CNFs
showed strong anti-leishmanial activity against Leishmania donovani intramacrophage amastigotes
while minimizing cytotoxicity to host cells. This innovative approach presents a promising
therapeutic alternative, combining targeted delivery with reduced side effects to effectively address
the persistent challenges in treating leishmaniasis.
